DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q3 EPS of ($0.15), $0.01 better than the analyst estimate of ($0.16).

For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) click here.